CR20110186A - Formulación farmacéutica 514 - Google Patents

Formulación farmacéutica 514

Info

Publication number
CR20110186A
CR20110186A CR20110186A CR20110186A CR20110186A CR 20110186 A CR20110186 A CR 20110186A CR 20110186 A CR20110186 A CR 20110186A CR 20110186 A CR20110186 A CR 20110186A CR 20110186 A CR20110186 A CR 20110186A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical formulation
copovidone
drug
softening temperature
solid dispersion
Prior art date
Application number
CR20110186A
Other languages
English (en)
Inventor
Michael Karl Bechtold
Claudia Bettina Packhaeuser
Julie Kay Cahill
Katja Maren Fastnacht
Bernd Harald Liepold
Kieran James Lennon
Benedikt Steitz
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41396997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110186(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of CR20110186A publication Critical patent/CR20110186A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica que contiene el fármaco en una dispersión sólida con un polímero de matriz que tiene baja higroscopicidad y elevada temperatura de ablandamiento, como copovidona.
CR20110186A 2008-10-07 2011-04-07 Formulación farmacéutica 514 CR20110186A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10334708P 2008-10-07 2008-10-07

Publications (1)

Publication Number Publication Date
CR20110186A true CR20110186A (es) 2011-08-09

Family

ID=41396997

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110186A CR20110186A (es) 2008-10-07 2011-04-07 Formulación farmacéutica 514

Country Status (43)

Country Link
US (11) US8475842B2 (es)
EP (1) EP2346495B2 (es)
JP (1) JP5524220B2 (es)
KR (1) KR101668499B1 (es)
CN (1) CN102238945B (es)
AR (2) AR073792A1 (es)
AU (1) AU2009300866B2 (es)
BR (2) BRPI0920604B1 (es)
CA (1) CA2737400C (es)
CL (1) CL2011000774A1 (es)
CO (1) CO6361906A2 (es)
CR (1) CR20110186A (es)
CU (1) CU24032B1 (es)
CY (2) CY1118190T1 (es)
DK (1) DK2346495T4 (es)
DO (1) DOP2011000094A (es)
EA (1) EA020783B1 (es)
EC (1) ECSP11010960A (es)
ES (1) ES2598178T5 (es)
FI (1) FI2346495T4 (es)
HK (1) HK1158528A1 (es)
HN (1) HN2011000947A (es)
HR (1) HRP20161154T4 (es)
HU (2) HUE030800T2 (es)
IL (1) IL211809A (es)
LT (2) LT2346495T (es)
ME (1) ME02640B (es)
MX (1) MX2011003740A (es)
MY (1) MY160340A (es)
NI (1) NI201100070A (es)
NO (1) NO2018038I1 (es)
NZ (1) NZ592719A (es)
PE (1) PE20110893A1 (es)
PL (1) PL2346495T5 (es)
PT (1) PT2346495T (es)
RS (1) RS55157B2 (es)
SA (1) SA109300599B1 (es)
SI (1) SI2346495T2 (es)
TW (1) TWI461418B (es)
UA (1) UA106878C2 (es)
UY (1) UY32162A (es)
WO (1) WO2010041051A1 (es)
ZA (1) ZA201103333B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
JP5823484B2 (ja) * 2010-07-14 2015-11-25 千寿製薬株式会社 α―ケトアミド誘導体固体分散体
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2811805A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
KR101923364B1 (ko) 2010-11-23 2018-11-30 애브비 인코포레이티드 아폽토시스­유도제의 염 및 결정형
DK2642999T3 (en) 2010-11-23 2017-01-09 Abbvie Ireland Unlimited Co METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
MY172729A (en) * 2011-11-23 2019-12-11 Array Biopharma Inc Pharmaceutical formulations
NL2009367C2 (en) * 2012-08-27 2014-03-03 Stichting Vu Vumc Microscopic imaging apparatus and method to detect a microscopic image.
BR112015012425A2 (pt) 2012-12-31 2017-07-11 Cadila Healthcare Ltd composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
CN105777651A (zh) * 2015-01-13 2016-07-20 江苏豪森药业集团有限公司 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
CA2981627C (en) 2015-04-03 2024-02-20 Suixiong Cai Solid pharmaceutical formulation of parp inhibitors and the use thereof
CN106265580B (zh) * 2015-05-18 2020-09-08 中国科学院上海药物研究所 Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
CN112010809A (zh) * 2015-06-12 2020-12-01 苏州科睿思制药有限公司 奥拉帕尼的晶型i及其制备方法
US20170105937A1 (en) * 2015-10-16 2017-04-20 Cadila Healthcare Limited Olaparib co-precipitate and preparation method thereof
CN105254572A (zh) * 2015-11-09 2016-01-20 北京科莱博医药开发有限责任公司 一种奥拉帕尼的晶型及其制备方法和应用
ITUB20159206A1 (it) * 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
US20170204067A1 (en) 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
CN108201536A (zh) * 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
AU2018282883B2 (en) * 2017-06-12 2024-03-28 Protein Dynamic Solutions, Inc. Method and system for analysis of crystals and crystallization
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
CN109293576A (zh) * 2018-11-08 2019-02-01 威海贯标信息科技有限公司 一种小粒度奥拉帕尼的制备方法
CN115645370A (zh) * 2018-11-16 2023-01-31 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
CN110013466B (zh) * 2019-05-28 2021-11-30 天津中医药大学 一种小檗红碱固体分散体粉末及制备方法及应用
US10703728B1 (en) * 2019-06-18 2020-07-07 Scinopharm Taiwan, Ltd. Crystalline form of olaparib and a process for preparing the same
EP4079295A4 (en) * 2019-12-20 2023-12-06 Samyang Holdings Corporation COMPOSITION HAVING IMPROVED SOLUBILITY AND BIOAVAILABILITY OF OLAPARIB
CA3161892A1 (en) 2019-12-23 2021-07-01 Jie Fan Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
KR20220124739A (ko) 2020-01-09 2022-09-14 아스트라제네카 아베 암의 치료를 위한 병용 요법
CN113288859A (zh) 2020-02-21 2021-08-24 上海宣泰医药科技股份有限公司 奥拉帕尼药物组合物及其制剂、制备方法和用途
CN113350349B (zh) * 2020-03-04 2022-11-11 中国科学院上海药物研究所 奥拉帕尼溶出增强组合物
WO2022058785A1 (en) 2020-09-16 2022-03-24 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
KR20220077094A (ko) * 2020-12-01 2022-06-08 주식회사 삼양홀딩스 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
CN112843007A (zh) * 2021-02-04 2021-05-28 石药集团中奇制药技术（石家庄）有限公司 一种奥拉帕利片
EP4351519A1 (en) * 2021-06-07 2024-04-17 Zerion Pharma Aps Co-amorphous forms for use in cancer therapy
WO2023084311A1 (en) 2021-11-10 2023-05-19 Nuformix Technologies Limited Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
WO2023174948A2 (en) * 2022-03-14 2023-09-21 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics and uses thereof
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2143745A1 (de) 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en) 1974-03-01 1975-09-26 Delalande Sa 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
JPS54156526A (en) 1978-05-31 1979-12-10 Asahi Chemical Ind Dry picture forming material
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
JPS58164577A (ja) 1982-03-24 1983-09-29 Taiho Yakuhin Kogyo Kk ４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4665181A (en) 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
DE3677322D1 (de) 1985-11-11 1991-03-07 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
DE3612212A1 (de) † 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8610018D0 (en) 1986-04-24 1986-05-29 Fujisawa Pharmaceutical Co Phthalazine derivatives
DE3640641A1 (de) 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ZA882639B (en) 1987-05-02 1988-09-30 Asta-Pharma Aktiengesellschaft New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives
JP2786896B2 (ja) 1988-08-19 1998-08-13 ワーナー―ランバート・コンパニー 置換されたジヒドロイソキノリノンおよび関連化合物
DE69019774T2 (de) 1989-03-28 1995-11-09 Nisshin Flour Milling Co Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
DD287032A5 (de) 1989-07-28 1991-02-14 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
AU3440693A (en) 1992-01-17 1993-08-03 Syntex (U.S.A.) Inc. Substituted 1-isoquinolone derivatives as angiotensin II antagonists
CZ199593A3 (en) 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
JPH08502973A (ja) 1992-11-02 1996-04-02 メルク エンド カンパニー インコーポレーテッド ニューロテンシンアンタゴニストとしての置換フタラジノン
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AU691331B2 (en) 1994-08-12 1998-05-14 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
AU686004B2 (en) 1994-08-12 1998-01-29 Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
EP0721286A3 (en) 1995-01-09 2000-07-26 Matsushita Electric Industrial Co., Ltd. Video signal decoding apparatus with artifact reduction
MX9707561A (es) 1995-04-07 1997-12-31 Schering Corp Compuestos de carbonil piperazinilo y piperidinilo.
US6127367A (en) 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
AU727939B2 (en) 1996-04-03 2001-01-04 Merck & Co., Inc. A method of treating cancer
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038664A2 (en) 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
WO1997045412A1 (en) 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
CN1136197C (zh) 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5888529A (en) 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
NZ501650A (en) 1997-05-13 2001-11-30 Octamer Inc Use of a pADPRT inhibitory compound that is not 3-aminobenzamide to treat inflammation and inflammatory diseases in mammals
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
CA2310250A1 (en) 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US20060084660A1 (en) 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US6943168B2 (en) 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6951862B2 (en) 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US20040259866A1 (en) 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US20040266784A1 (en) 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
JP4093448B2 (ja) 1999-01-11 2008-06-04 アグロン・ファーマシューティカルズ・インコーポレーテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
HUP0202448A3 (en) 1999-08-11 2005-02-28 Bristol Myers Squibb Co Process for preparation of paclitaxel c-4 methyl carbonate analog
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
WO2001021615A1 (en) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
CN1374961A (zh) 1999-09-28 2002-10-16 巴斯福股份公司 氮杂䓬吲哚衍生物,它们的制备和应用
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
DE19963607B4 (de) 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
AU2001240542A1 (en) 2000-02-01 2001-08-14 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
WO2001079184A1 (fr) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Composes de piperazine substitues
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US20030176454A1 (en) 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CA2412215A1 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1330442B1 (en) 2000-10-30 2011-01-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002044157A2 (en) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
EP1575478A2 (en) * 2001-12-28 2005-09-21 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
EP1477175B1 (en) 2002-02-19 2011-04-27 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
BR0307944A (pt) 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
PL1633724T3 (pl) † 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) † 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2547077C (en) 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
EP1744751A4 (en) 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
US20050227999A1 (en) 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
DE102005011822A1 (de) 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US20080221047A1 (en) * 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
CN103690542B (zh) 2006-12-28 2015-11-18 Abbvie公司 聚(adp-核糖)聚合酶抑制剂
EP1958615A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
EP2346495B2 (en) † 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514

Also Published As

Publication number Publication date
EP2346495A1 (en) 2011-07-27
PT2346495T (pt) 2016-11-11
US20230338372A1 (en) 2023-10-26
RS55157B1 (sr) 2017-01-31
LTPA2018014I1 (lt) 2018-12-10
US11975001B2 (en) 2024-05-07
CO6361906A2 (es) 2012-01-20
EP2346495B2 (en) 2023-05-24
HRP20161154T4 (hr) 2023-09-29
SI2346495T1 (sl) 2016-10-28
CY2018030I2 (el) 2019-11-27
LT2346495T (lt) 2016-10-10
ES2598178T5 (es) 2023-12-26
CN102238945A (zh) 2011-11-09
US11633396B2 (en) 2023-04-25
BRPI0920604B1 (pt) 2021-11-23
CA2737400C (en) 2016-11-22
MX2011003740A (es) 2011-05-02
MY160340A (en) 2017-02-28
CN102238945B (zh) 2014-10-29
ME02640B (me) 2017-06-20
EA201100595A1 (ru) 2011-12-30
CU24032B1 (es) 2014-10-02
US20160008473A1 (en) 2016-01-14
KR20110066942A (ko) 2011-06-17
AR073792A1 (es) 2010-12-01
UA106878C2 (uk) 2014-10-27
US20230346780A1 (en) 2023-11-02
WO2010041051A1 (en) 2010-04-15
NI201100070A (es) 2012-03-19
FI2346495T4 (fi) 2023-08-31
DOP2011000094A (es) 2011-07-15
US8475842B2 (en) 2013-07-02
UY32162A (es) 2010-05-31
EA020783B1 (ru) 2015-01-30
ES2598178T3 (es) 2017-01-25
AR116035A2 (es) 2021-03-25
US20180133216A1 (en) 2018-05-17
US20170173010A1 (en) 2017-06-22
HN2011000947A (es) 2014-02-17
PE20110893A1 (es) 2012-01-18
AU2009300866B2 (en) 2013-03-28
US20190365751A1 (en) 2019-12-05
US20230000862A1 (en) 2023-01-05
JP2012505158A (ja) 2012-03-01
EP2346495B1 (en) 2016-07-20
TWI461418B (zh) 2014-11-21
RS55157B2 (sr) 2023-10-31
KR101668499B1 (ko) 2016-10-21
HUS1800043I1 (hu) 2018-11-28
SI2346495T2 (sl) 2023-10-30
CA2737400A1 (en) 2010-04-15
PL2346495T3 (pl) 2017-02-28
AU2009300866A1 (en) 2010-04-15
ZA201103333B (en) 2012-01-25
DK2346495T3 (en) 2016-09-26
CU20110080A7 (es) 2011-12-28
ECSP11010960A (es) 2011-05-31
IL211809A0 (en) 2011-06-30
US20200323847A1 (en) 2020-10-15
NO2018038I1 (no) 2018-11-07
BR122021018683B1 (pt) 2022-11-16
SA109300599B1 (ar) 2014-02-17
JP5524220B2 (ja) 2014-06-18
US20140066447A1 (en) 2014-03-06
US20220249474A1 (en) 2022-08-11
HK1158528A1 (zh) 2012-07-20
NZ592719A (en) 2012-09-28
CY1118190T1 (el) 2017-06-28
HUE030800T2 (en) 2017-05-29
BRPI0920604A2 (pt) 2020-09-15
US20100098763A1 (en) 2010-04-22
CY2018030I1 (el) 2019-11-27
DK2346495T4 (da) 2023-08-28
TW201018671A (en) 2010-05-16
PL2346495T5 (pl) 2024-06-10
IL211809A (en) 2014-12-31
CL2011000774A1 (es) 2011-08-05
HRP20161154T1 (hr) 2016-11-18

Similar Documents

Publication Publication Date Title
CR20110186A (es) Formulación farmacéutica 514
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BRPI1002587A2 (pt) composição e produto de reação
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
BR112015021002B8 (pt) Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo
BR112014004460A2 (pt) material polimérico para um recipiente isolado
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
ECSP099320A (es) Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
BR112012024432A2 (pt) composição farmacêutica de dissolução rápida
BRPI0720153A8 (pt) Composições e artigos que contêm uma matriz de polímero reticulada e um líquido ativo imobilizado assim como processos de utilização dos mesmos
BR112015000112A2 (pt) composição antimicrobiana endurecível
ECSP12011735A (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
UY31785A1 (es) Sistema polimerico de lagrimas artificiales
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
CL2017002659A1 (es) Marcadores genéticos asociados con la tolerancia a la sequía en el maíz (solicitud divisional de 1032-2015)
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
BR112012024428A2 (pt) composição farmacêutica de dissolução rápida
BR112014029264A2 (pt) microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo
BRPI1011630B8 (pt) paracetamol para a administração parenteral
AR075301A1 (es) Composicion y metodo para controlar enfermedades de plantas